Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

112.50USD
3:14pm EDT
Change (% chg)

$-3.11 (-2.69%)
Prev Close
$115.61
Open
$116.24
Day's High
$116.43
Day's Low
$111.60
Volume
106,527
Avg. Vol
157,698
52-wk High
$177.74
52-wk Low
$96.76

Latest Key Developments (Source: Significant Developments)

Intercept Pharmaceuticals reports Q4 sales $13.8 mln
Thursday, 23 Feb 2017 07:05am EST 

Intercept Pharmaceuticals Inc : Q4 sales $13.8 million . Intercept pharmaceuticals reports full year 2016 financial results and provides business update . Q4 revenue view $9 million -- Thomson Reuters I/B/E/S . Intercept pharmaceuticals inc sees NON-GAAP adjusted operating expenses of $380 million to $420 million for fiscal year ending december 31, 2017 .Qtrly loss per share $4.84.  Full Article

Intercept says European Commission grants Ocaliva marketing authorization
Wednesday, 14 Dec 2016 07:00am EST 

Intercept Pharmaceuticals Inc : European Commission grants Intercept's Ocaliva (obeticholic acid) marketing authorization for the treatment of primary biliary cholangitis .Intercept Pharmaceuticals-as conditions of approval, co required to provide post-approval updates on safety, efficacy analyses for Ocaliva.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 07:00am EDT 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Intercept Pharmaceuticals Q2 net loss per share $3.14
Thursday, 4 Aug 2016 07:05am EDT 

Intercept Pharmaceuticals Inc : Intercept pharmaceuticals reports second quarter 2016 financial results and provides business update . Net ocaliva 2q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenue . Q2 earnings per share view $-3.70, revenue view $1.5 million -- Thomson Reuters I/B/E/S . Qtrly net loss per share diluted $3.14 .Qtrly total revenue $5.5 million versus $445,000.  Full Article

Intercept Pharmaceuticals announces pricing of public offering
Thursday, 30 Jun 2016 09:18am EDT 

Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals announces pricing of public offering of convertible senior notes.  Full Article

Intercept Pharmaceuticals files for convertible senior notes for up to $400 mln
Wednesday, 29 Jun 2016 05:08pm EDT 

Intercept Pharmaceuticals Inc :Files for convertible senior notes for up to $400 million - SEC filing.  Full Article

Intercept Pharmaceuticals announces public offering of convertible senior notes
Wednesday, 29 Jun 2016 04:15pm EDT 

Intercept Pharmaceuticals Inc : Announces public offering of convertible senior notes . Says commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 .Says intends to use a portion of net proceeds from offering to fund payment of cost of capped call transactions.  Full Article

Intercept Pharmaceuticals Inc - FDA delays decision on lead drug - Reuters
Thursday, 17 Dec 2015 06:22pm EST 

Intercept Pharmaceuticals Inc:U.S. FDA postpones ruling on marketing application for Intercept's lead drug by three months to analyze additional clinical data - RTRS.  Full Article

Intercept Pharmaceuticals announces initiation of prospective trial to explore effect of combined oca and statin therapy on lipid metabolism in NASH Patients
Monday, 7 Dec 2015 07:10am EST 

Intercept Pharmaceuticals Inc :Announces initiation of prospective trial to explore effect of combined oca and statin therapy on lipid metabolism in nash patients.Trial will include a 16-week double-blind phase followed by optional two-year long-term safety extension phase.  Full Article

Intercept Pharmaceuticals, Inc announces results of phase 2 Trial of OCA in NASH Patients in Japan
Wednesday, 28 Oct 2015 07:30am EDT 

Intercept Pharmaceuticals, Inc:Announces results of phase 2 trial of oca in nash patients in Japan.Says 40mg oca dose group achieved statistical significance on the primary endpoint compared to placebo.  Full Article

More From Around the Web

BRIEF-Intercept Pharmaceuticals reports Q4 sales $13.8 mln

* Intercept pharmaceuticals reports full year 2016 financial results and provides business update